Stock surge of Nektar Therapeutics exceeded 15% today
Nektar Therapeutics, a clinical-stage biotech company, has made a significant stride in the treatment of inflammatory skin disorders. The company recently published new data from a phase 2b study of their investigational therapy, rezpegaldesleukin, which targets moderate to severe atopic dermatitis.
According to Nektar's chief research and development officer, Jonathan Zalevsky, rezpegaldesleukin utilizes regulatory T-cells (Tregs) as a therapeutic modality. Tregs have shown potential in treating inflammatory skin disorders, as demonstrated by the results of the atopic dermatitis trial.
The high dose of rezpegaldesleukin achieved statistical significance on its primary endpoint, improvement in the eczema area and severity index, versus a placebo over 16 weeks of treatment. Moreover, the company reported that rezpegaldesleukin was generally well tolerated by the study's participants.
The encouraging news sent Nektar Therapeutics' stock soaring on the stock market today. The stock closed the trading session more than 15% higher, outperforming the 0.5% advance of the S&P 500 index. The day's range of the stock was $52.13 - $58.81, with a volume of 1,876,452. The average volume of Nektar Therapeutics' stock is 2,218,224.
Nektar Therapeutics is currently developing rezpegaldesleukin for the treatment of severe alopecia areata, a disease causing hair loss. The next readout from clinical testing for alopecia areata treatment is expected in December. Participants who continued taking rezpegaldesleukin experienced even more profound effects, offering hope for patients suffering from this condition.
With a market capitalization of $1B, Nektar Therapeutics continues to make strides in the biotech industry. The company's focus on innovative treatments for inflammatory skin disorders positions it well for future growth.
Read also:
- High recovery rate for over 90% of patients, asserts the head physician of Almaty's 32nd polyclinic, regarding mobile treatment groups.
- Bee colonies in Zirndorf city have been affected by American foulbrood - a designated restriction zone has been established - no immediate threat to local residents.
- Federal Health Care Blueprint for 2026 Revealed by OPM Outlining Key Strategies and Objectives
- Unveiling the Undiscussed Issues of Earbuds: Revealing the Silent Reality
